Dr. Paula Brown Appointed to Board of Wholly Owned Subsidiary Biocell Laboratories Inc. and Acquires Formulations

Dr. Paula Brown Appointed to Board of Wholly Owned Subsidiary Biocell Laboratories Inc. and Acquires Formulations

VANCOUVER, March 4, 2013 /PRNewswire/ - Biocell Labs Inc., a wholly owned subsidiary of Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU), announces the engagement of Dr. Paula Brown to provide the Company with the expertise and assistance needed to expand its capacity into the production of novel bio-pharmaceutical products.

Mr. Mike Withrow, Chief Executive Officer on behalf of the Company, stated, "we are very pleased to have Dr. Brown join the Board of Biocell Labs Inc. with her extensive knowledge, the Company continues to deliver on its plan to become a fully integrated bioceutical company that offers cutting-edge proprietary products to the medicinal, nutraceutical and cosmetic industries."

Paula N. Brown, Ph.D., Director of Applied Research for BCIT's Natural Health & Food Products Research Group stated, "I am very excited about this opportunity to work with Biocell Labs Inc. to advance their integrated model, employing vertical automated growing systems and novel extraction technologies, to develop health and wellness products derived from medicinal plants." As far back as 2001 inconsistencies in raw materials, poor product quality and the absence of validated analytical methods have been identified as a public health risk and barrier to rigorous scientific study. Dr. Brown went on to state, "my research has grown out of a desire to apply scientific principles and advanced chemoanalytical tools to ensure consumers have confidence in the products they are ingesting."

Abattis Bioceutical Corporation would also like to announce that it has acquired from Dr. Brown a portfolio of natural health product formulas focusing on pain management, immunity & inflammation and cognitive function in exchange for 400,000 shares of Abattis.

The Biography of Dr. Paula Brown

Dr. Paula Brown, as Director of the BC Institute of Technology's Natural Health and Food Products Research Group, has been actively supporting the NHP industry for over a decade through applied research activities including product development, establishment of quality standards and regulatory compliance. By providing fundamental investigations on product quality, safety and efficacy, BCIT supports industry through the entire continuum, from grower to manufacturer, ensuring product integrity is maintained. Dr. Brown has spoken at numerous conferences over the last decade on product quality standards, analytical method validation and is currently Chair of NSF's Dietary Supplement Joint Committee. Dr. Brown sits on the advisory Board of the American Botanical Council, is a Fellow of the AOAC International having served as General Referee for the Dietary Supplement Methods Committee from 2004-2009, from 2008-2013 was "Quality Focus" columnist for Nutraceuticals World, an Industry Trade Journal published by Rodman Publishing. Dr. Brown has reviewed and contributed to several American Herbal Pharmacopeia Monographs including Black Cohosh and Ginseng.

About Abattis Bioceuticals Corp.
Abattis Bioceuticals Corp. is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of producing, licensing and marketing proprietary ingredients and products containing standardized phytochemicals for sale in Pharmaceutical, Nutraceutical, Cosmetic and Animal Nutrition markets. The company also has a deep pipeline of proprietary products ready for sale in high growth areas of Functional Foods and Supplements business. For more information, visit the Company's website at www.abattis.com.

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.